Short-time Clinical Therapeutic Effects Of Intravitreal Ranibizumab (Lucentis) Injection For Macular Edema

Objective To evaluate the short time clinical therapeutic efficacy and safety ofintravitreal Ranibizumab injection for macular edemaMethods Forty-two eyes with macular edema.the baseline examination include intraocular pressure(IOP),fundus fluorescein angiography(FFA）and thickness of theneurosensory retina and the central volume of macular measured with optical coherence tomography(OCT)at one day、one month、three months and six months follow-up.Results The BCVA of baseline was38.8±20.47letters,and the BCVA at one day、one month、three months and six months follow-up were46.9±16.83letters、55.3±17.19letters、57.5±18.19letters、54.8±17.8letters,and were significantly better than that at baseline(P=0.000,P=0.002,P=0.008,P=0.005),all the differences havestatistical significances.the one month follow-up BCVA had significant differencewith that at after one day(P=0.001).the three months follow-up BCVA had significant difference with that at after one month（P=0.000），the six months follow-upBCVA had significant difference with that at after three months（P=0.000）.After six months follow-up,the BCVA had significant difference compared to that at the baseline(P=0.003). the central retinal thickness(CRT) of baseline was660.29±336.5μm,the central retinal thickness(CRT) at one day、one month、three months and six months follow-up after injection were575.52±311.9μm、452.1±239.3μm、417.95±194.9μm、422.29±197.0μm,ane were reduced significantly compared to the baseline((P=0.000,P=0.000,P=0.000,P=0.000),all the differences have statistical significances.itat one month follow-up significantly reduced compared that at one day(P=0.001).At the three months,the central macular thickness had significant difference compared to that at after one month(P=0.000),at the six months, the central macular thickness had significant difference compared to that at after three months(P=0.003).At six months follow-up,the central macular thickness reduced significantlycompared to the baseline(P=0.000)the central macular volume(CMV) within1mm of baseline was0.3135±0.183mm3,the central macular volume(CMV) within1mm at one day、one month、three months and six months-up after injection were0.2689±0.152mm3、0.2397±0.113mm3、0.2181±0.095mm3、0.2078±0.096mm3,and were reduced significantly compared to the baseline((P=0.000,P=0.000,P=0.002,P=0.001),all the differences have statistical significances.the two months follow-upthe central macular volume(CMV) within1mm had significant difference with that at after one month（P=0.000），the three months follow-up BCVA had significant difference with that at after two months（P=0.004）.After six months follow-up,the the central macular volume(CMV) within1mm had significant differencecompared to that at the baseline(P=0.002).At the six months follow-up,the meanIOP was normal.All patients had no complications such as inflammation,infectiousendophthalmitis,vitreous hemorrhage and retinal detachment. ConclusionWith the method of the measurement of the central macular volume(CMV),The Intravitreal Ranibizumab injection is a relatively safe and effective treatmentmethod for the short-term control of macular edema with less complications visualized，and also could be better illustrate the outcome of the disease with the method of measuring of CMV.